Abstracts tagged "Intervention"

Abstract Number: 2098 • 2013 ACR/ARHP Annual Meeting
What Elements Of Physical Therapy Interventions Contribute To Improved Outcomes Following Total Knee Arthroplasty
Joshua K Johnson¹, Traci E DeWan¹, Kelly L Donahue¹, Wenjun Li², Patricia D. Franklin² and Carol A. Oatis¹, ¹Physical Therapy, Arcadia University, Glenside, PA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Functional outcomes are variable among patients following total knee arthroplasty (TKA). Evidence is lacking to support best practices in rehabilitation to optimize functional outcomes.…
Abstract Number: 987 • 2013 ACR/ARHP Annual Meeting
Improving Access To Subspecialty Care For Underserved Communities: A Rheumatology Patient Navigator Pilot Intervention
Candace H. Feldman¹, Gregory A. Culley², Erika Brown³, Chanele R. Assencoa², LeRoi S. Hicks⁴ and Daniel H. Solomon^3,5, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital,Harvard Medical School, Boston, MA, ²Family Health Center of Worcester, Inc., Worcester, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Hospital Medicine, UMass Memorial Medical Center, Worcester, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Early and sustained access to rheumatology care can improve access to disease-modifying medications and reduce disparities in outcomes. In one state, more than one-half…
Abstract Number: 898 • 2013 ACR/ARHP Annual Meeting
Sex-Specific Employment Participation Restriction Across Occupational Groups Among Working-Age (18-64 years) U.S. Adults With and Without Arthritis
Kristina A. Theis¹ and Louise Murphy², ¹Athritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²Division of Population Health, CDC, Atlanta, GA
Background/Purpose: Previous research has shown arthritis-attributable work limitation to be high (~30%) among U.S. adults with arthritis and for employment to be ~20% lower among…
Abstract Number: 570 • 2013 ACR/ARHP Annual Meeting
In Vivo Therapeutic Success Of Microrna-155 (miR-155) Antagomir In a Mouse Model Of Lupus Pulmonary Hemorrhage
Shiyu Zhou¹, Dong Liang², Xinfang Huang³, Chunyuan Xiao³, Yuanjia Tang¹, Qian Jia³, John B. Harley^4,5 and Nan Shen^6,7,8, ¹Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology ,Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, ⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Rheumatology, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, OH, China, ⁷Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, cincinnati, OH, ⁸Shanghai Institute of Rheumatology ,Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
Background/Purpose: MiR-155 is a typical pleiotropic miRNA that participates in various aspects of immunity. Previous in vitro studies indicated that it is both a pro-inflammatory and an anti-inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].